pmid	doi	year	title	Hugo_Symbol
34216243	10.1007/s00277-021-04572-2	2022	Liquid biopsies of plasma and cerebrospinal fluid are useful for detection of intravascular lymphoma with central nervous system symptoms alone.	CD79B
34232979	10.1182/blood.2020010039	2022	The alternative RelB NF-κB subunit is a novel critical player in diffuse large B-cell lymphoma.	CD79B
34448823	10.1182/bloodadvances.2021004212	2022	The molecular hallmarks of primary and secondary vitreoretinal lymphoma.	CD79B
34638136	10.1182/bloodadvances.2020003698	2022	Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma.	CD79B
34654055	10.1182/bloodadvances.2021006034	2022	Diffuse large B-cell lymphomas in adults with aberrant coexpression of CD10, BCL6, and MUM1 are enriched in IRF4 rearrangements.	CD79B
34672246	10.1080/10428194.2021.1980214	2022	Cytoplasmic CD79a is a promising biomarker for B lymphoblastic leukemia follow up post CD19 CAR-T therapy.	CD79B
34904799	10.1056/NEJMoa2115304	2022	Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.	CD79B
34980599	10.1158/1078-0432.CCR-21-3261	2022	Anti-CD79B Antibody-Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study.	CD79B
35028710	10.1007/s00428-021-03265-5	2022	Cell-of-origin classification using the Hans and Lymph2Cx algorithms in primary cutaneous large B-cell lymphomas.	CD79B
35126963	10.1177/20406207211072839	2022	MYD88<sup>L265P</sup> and CD79B double mutations type (MCD type) of diffuse large B-cell lymphoma: mechanism, clinical characteristics, and targeted therapy.	CD79B
35169086	10.11477/mf.1436204531	2022	[Perspectives on Precision Medicine in Primary Central Nervous System Lymphoma].	CD79B
35179642	10.1007/s00277-021-04394-2	2022	CD20/CD79a/PAX5/CD3-negative post-transplant lymphoma with aberrant actin and desmin co-expression-a potential differential diagnostic pitfall between PTLD and PTSMT.	CD79B
35210172	10.1016/j.preteyeres.2022.101053	2022	Challenges in the diagnosis and management of vitreoretinal lymphoma - Clinical and basic approaches.	CD79B
35223507	10.3389/fonc.2022.824632	2022	<i>PIM1</i> and <i>CD79B</i> Mutation Status Impacts the Outcome of Primary Diffuse Large B-Cell Lymphoma of the CNS.	CD79B
35236331	10.1186/s12885-022-09237-5	2022	Prognostic mutational subtyping in de novo diffuse large B-cell lymphoma.	CD79B
35240681	10.1182/bloodadvances.2021006801	2022	A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapy.	CD79B
35255429	10.1016/j.anndiagpath.2021.151886	2022	De Novo CD5-positive diffuse large B-cell lymphoma: A genomic profiling study and prognostic analysis of 46 patients.	CD79B
35326604	10.3390/cancers14061453	2022	DLBCL 1L-What to Expect beyond R-CHOP?	CD79B
35401516	10.3389/fimmu.2022.842439	2022	Oncogenic Mutations and Tumor Microenvironment Alterations of Older Patients With Diffuse Large B-Cell Lymphoma.	CD79B
35484253	10.1007/s00277-022-04827-6	2022	Richter's syndrome in central nervous system with MYD88L265P and CD79b mutation responded well to ibrutinib containing chemotherapy: a case report and review of the literature.	CD79B
35538064	10.1038/s41467-022-30050-y	2022	The genomic and transcriptional landscape of primary central nervous system lymphoma.	CD79B
35554927	10.1002/eji.202149746	2022	Spatial transcriptome of a germinal center plasmablastic burst hints at MYD88/CD79B mutants-enriched diffuse large B-cell lymphomas.	CD79B
35646048	10.3389/fgene.2022.878618	2022	Whole-Genome/Exome Sequencing Uncovers Mutations and Copy Number Variations in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System.	CD79B
35663281	10.1016/j.lrr.2022.100325	2022	Immunotherapy in indolent Non-Hodgkin's Lymphoma.	CD79B
35726803	10.1080/14737140.2022.2093191	2022	Polatuzumab vedotin in relapsed / refractory aggressive B-cell lymphoma.	CD79B
35759728	10.1182/blood.2022015926	2022	Aberrant expansion of spontaneous splenic germinal centers induced by hallmark genetic lesions of aggressive lymphoma.	CD79B
35764309	10.1111/bjh.18341	2022	The molecular rationale for the combination of polatuzumab vedotin plus rituximab in diffuse large B-cell lymphoma.	CD79B
35807041	10.3390/jcm11133748	2022	BeEAM High-Dose Chemotherapy with Polatuzumab (Pola-BeEAM) before ASCT in Patients with DLBCL-A Pilot Study.	CD79B
35908982	10.1016/j.blre.2022.100992	2022	Follicular lymphoma: The long and winding road leading to your cure?	CD79B
35917107	10.1111/bjh.18384	2022	United we stand: Double targeting of CD79B and CD20 in diffuse large B-cell lymphoma.	CD79B
35928872	10.3389/fonc.2022.932674	2022	Cell-Free DNA Sequencing of Intraocular Fluid as Liquid Biopsy in the Diagnosis of Vitreoretinal Lymphoma.	CD79B
35933930	10.1016/j.ctrv.2022.102443	2022	Treatment strategies for patients with diffuse large B-cell lymphoma.	CD79B
35937947	10.1155/2022/6441139	2022	Genomic Mutation Landscape of Primary Breast Lymphoma: Next-Generation Sequencing Analysis.	CD79B
35963895	10.1007/s00262-022-03267-5	2022	Characterization of anti-CD79b/CD3 bispecific antibody, a potential therapy for B cell malignancies.	CD79B
36006771	10.1097/PAS.0000000000001957	2022	Clinicopathologic Features and Genomic Signature of De Novo CD5+ Diffuse Large B-Cell Lymphoma: A Multicenter Collaborative Study.	CD79B
36051079	10.1002/jha2.428	2022	Targetable alterations in primary extranodal diffuse large B-cell lymphoma.	CD79B
36059608	10.3389/fonc.2022.955080	2022	Circulating cell-free DNA and IL-10 from cerebrospinal fluids aid primary vitreoretinal lymphoma diagnosis.	CD79B
36081566	10.3389/fonc.2022.941347	2022	Molecular subtyping of CD5+ diffuse large B-cell lymphoma based on DNA-targeted sequencing and Lymph2Cx.	CD79B
32273478	10.3324/haematol.2020.251579	2021	Genetic lesions in MYC and STAT3 drive oncogenic transcription factor overexpression in plasmablastic lymphoma.	CD79B
32500753	10.1080/14712598.2020.1777979	2021	Polatuzumab vedotin for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma.	CD79B
32583848	10.1093/neuonc/noaa145	2021	Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma.	CD79B
32954807	10.2217/fon-2020-0675	2021	Polatuzumab vedotin, an anti-CD79b antibody-drug conjugate for the treatment of relapsed/refractory diffuse large B-cell lymphoma.	CD79B
33202420	10.1182/blood.2020008520	2021	EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity.	CD79B
33232972	10.1182/blood.2020005244	2021	Adaptive T-cell immunity controls senescence-prone MyD88- or CARD11-mutant B-cell lymphomas.	CD79B
33273056	10.1158/1535-7163.MCT-20-0046	2021	An Anti-CD22-<i>seco</i>-CBI-Dimer Antibody-Drug Conjugate (ADC) for the Treatment of Non-Hodgkin Lymphoma That Provides a Longer Duration of Response than Auristatin-Based ADCs in Preclinical Models.	CD79B
33314668	10.1111/ijlh.13420	2021	Downregulation of Lymphoid enhancer-binding factor 1 (LEF-1) expression (by immunohistochemistry and/ flow cytometry) in chronic Lymphocytic Leukemia with atypical immunophenotypic and cytologic features.	CD79B
33452395	10.1038/s41598-021-81000-5	2021	EBF1 drives hallmark B cell gene expression by enabling the interaction of PAX5 with the MLL H3K4 methyltransferase complex.	CD79B
33452446	10.1038/s42003-020-01591-z	2021	CD79a promotes CNS-infiltration and leukemia engraftment in pediatric B-cell precursor acute lymphoblastic leukemia.	CD79B
33479306	10.1038/s41598-020-80376-0	2021	Proposal and validation of a method to classify genetic subtypes of diffuse large B cell lymphoma.	CD79B
33512416	10.1182/blood.2020007245	2021	Frequent genetic alterations in immune checkpoint-related genes in intravascular large B-cell lymphoma.	CD79B
33561953	10.3390/cancers13040650	2021	Spatial Heterogeneity in Large Resected Diffuse Large B-Cell Lymphoma Bulks Analysed by Massively Parallel Sequencing of Multiple Synchronous Biopsies.	CD79B
33562532	10.3390/cancers13040630	2021	Large-Scale Proteomic Analysis of Follicular Lymphoma Reveals Extensive Remodeling of Cell Adhesion Pathway and Identifies Hub Proteins Related to the Lymphomagenesis.	CD79B
33581493	10.1016/j.ctarc.2021.100310	2021	Diversity of genetic alterations of primary central nervous system lymphoma in Hispanic versus non-Hispanic patients.	CD79B
33583077	10.1002/hon.2842	2021	Real-life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B-cell lymphomas.	CD79B
33639170	10.1016/j.jbc.2021.100465	2021	TNF receptor-associated factor 3 restrains B-cell receptor signaling in normal and malignant B cells.	CD79B
33747936	10.3389/fonc.2021.622648	2021	Genomic Mutation Profile of Primary Gastrointestinal Diffuse Large B-Cell Lymphoma.	CD79B
33777778	10.3389/fonc.2021.628807	2021	Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma.	CD79B
33935029	10.5045/br.2021.2020320	2021	Novel combination immunochemotherapy beyond CD20 for B-cell lymphomas.	CD79B
33940156	10.1016/j.ymthe.2021.04.038	2021	Composite CD79A/CD40 co-stimulatory endodomain enhances CD19CAR-T cell proliferation and survival.	CD79B
33942442	10.1111/cas.14937	2021	A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B-cell lymphoma.	CD79B
34061467	10.1002/cam4.3983	2021	A new score including CD43 and CD180: Increased diagnostic value for atypical chronic lymphocytic leukemia.	CD79B
34204385	10.3390/cancers13123032	2021	Cell-Free Total Nucleic Acid-Based Genotyping of Aggressive Lymphoma: Comprehensive Analysis of Gene Fusions and Nucleotide Variants by Next-Generation Sequencing.	CD79B
34236648	10.1007/978-1-0716-1669-7_20	2021	Generation and Surgical Analysis of Genetic Mouse Models to Study NF-κB-Driven Pathogenesis of Diffuse Large B Cell Lymphoma.	CD79B
34254378	10.1111/neup.12739	2021	Primary central nervous system lymphomas with massive intratumoral hemorrhage: Clinical, radiological, pathological, and molecular features of six cases.	CD79B
34256851	10.1186/s40364-021-00309-5	2021	Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.	CD79B
34323286	10.1002/eji.202048968	2021	Bruton's tyrosine kinase inhibition induces rewiring of proximal and distal B-cell receptor signaling in mice.	CD79B
34327781	10.1111/cas.15091	2021	Current progress and future perspectives of research on intravascular large B-cell lymphoma.	CD79B
34595463	10.2991/chi.k.210305.001	2021	Polatuzumab Vedotin: Current Role and Future Applications in the Treatment of Patients with Diffuse Large B-Cell Lymphoma.	CD79B
34604075	10.3389/fonc.2021.737645	2021	Salvage Therapy With Polatuzumab Vedotin, Bendamustine, and Rituximab Prior to Allogeneic Hematopoietic Transplantation in Patients With Aggressive Lymphomas Relapsing After Therapy With Chimeric Antigen Receptor T-Cells-Report on Two Cases.	CD79B
34657049		2021	[Circulating Tumor DNA Analysis in Lymphomas].	CD79B
34706776	10.1186/s13256-021-03128-2	2021	Immunophenotypic challenges in diagnosis of CD79a negativity in a patient with B acute lymphoblastic leukemia harboring intrachromosomal amplification of chromosome 21: a case report.	CD79B
34706861	10.1136/bjophthalmol-2021-319580	2021	Prevalence and prognostic value of <i>MYD88</i> and <i>CD79B</i> mutations in ocular adnexal large B-cell lymphoma: a reclassification of ocular adnexal large B-cell lymphoma.	CD79B
34739844	10.1016/j.ccell.2021.10.006	2021	Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL.	CD79B
34745101	10.3389/fimmu.2021.732006	2021	International Prognostic Index-Based Immune Prognostic Model for Diffuse Large B-Cell Lymphoma.	CD79B
34768899	10.3390/ijms222111470	2021	Promising Immunotherapeutic Modalities for B-Cell Lymphoproliferative Disorders.	CD79B
34925435	10.3389/fgene.2021.677650	2021	Genetic Landscape of Relapsed and Refractory Diffuse Large B-Cell Lymphoma: A Systemic Review and Association Analysis With Next-Generation Sequencing.	CD79B
34944954	10.3390/cancers13246334	2021	Impact of a Faulty Germinal Center Reaction on the Pathogenesis of Primary Diffuse Large B Cell Lymphoma of the Central Nervous System.	CD79B
35116576	10.21037/tcr-20-2525	2021	Identification of key mutations in central nervous diffuse large B-cell lymphoma (DLBCL) by comprehensive analysis between sequencing and TCGA database.	CD79B
29629945	10.1097/PAI.0000000000000655	2020	Clonal Evolution in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System.	CD79B
31123031	10.3324/haematol.2018.214122	2020	<i>MYD88</i> mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis.	CD79B
31609782	10.1097/PAS.0000000000001386	2020	Morphologic Patterns and the Correlation With MYD88 L265P, CD79B Mutations in Primary Adrenal Diffuse Large B-Cell Lymphoma.	CD79B
31624374	10.1038/s41375-019-0607-5	2020	T cells redirected against Igβ for the immunotherapy of B cell lymphoma.	CD79B
31693429	10.1200/JCO.19.00172	2020	Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.	CD79B
31738823	10.1182/blood.2019002699	2020	Distinct molecular profile of IRF4-rearranged large B-cell lymphoma.	CD79B
31739126	10.1016/j.cancergen.2019.11.002	2020	Molecular and phenotypic characterization of an early T-cell precursor acute lymphoblastic lymphoma harboring PICALM-MLLT10 fusion with aberrant expression of B-cell antigens.	CD79B
31863183	10.1007/s00428-019-02698-3	2020	Lymphomas arising in immune-privileged sites: insights into biology, diagnosis, and pathogenesis.	CD79B
31894255	10.3892/ijmm.2019.4418	2020	Precision medicine for human cancers with Notch signaling dysregulation (Review).	CD79B
32056332	10.1111/cas.14347	2020	Gene expression profiling of primary vitreoretinal lymphoma.	CD79B
32060403	10.1038/s41375-020-0743-y	2020	Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma.	CD79B
32083995	10.1200/JCO.19.02314	2020	Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies.	CD79B
32127472	10.1073/pnas.1921187117	2020	Regulation of B cell receptor-dependent NF-κB signaling by the tumor suppressor KLHL14.	CD79B
32172360	10.1007/s11899-020-00572-7	2020	Polatuzumab Vedotin: a New Target for B Cell Malignancies.	CD79B
32201861	10.1093/noajnl/vdaa018	2020	Primary CNS lymphoma commonly expresses immune response biomarkers.	CD79B
32239385	10.1007/s11523-020-00710-4	2020	Genomic Alterations and MYD88<sup>MUT</sup> Variant Mapping in Patients with Diffuse Large B-Cell Lymphoma and Response to Ibrutinib.	CD79B
32309823	10.1358/dot.2020.56.4.3127026	2020	Polatuzumab vedotin to treat relapsed or refractory diffuse large B-cell lymphoma, in combination with bendamustine plus rituximab.	CD79B
32322395	10.1186/s40364-020-00189-1	2020	TBL1XR1 mutation predicts poor outcome in primary testicular diffuse large B-cell lymphoma patients.	CD79B
32399964	10.1002/ijc.33049	2020	Molecular profiling of Chinese R-CHOP treated DLBCL patients: Identifying a high-risk subgroup.	CD79B
32420699	10.1002/cam4.3136	2020	Serine-227 in the N-terminal kinase domain of RSK2 is a potential therapeutic target for mantle cell lymphoma.	CD79B
32495161	10.1007/s11523-020-00729-7	2020	Targeting CD79b for Chimeric Antigen Receptor T-Cell Therapy of B-Cell Lymphomas.	CD79B
32497402	10.1002/cyto.b.21887	2020	Contribution of immunophenotype to the investigation and differential diagnosis of Burkitt lymphoma, double-hit high-grade B-cell lymphoma, and single-hit MYC-rearranged diffuse large B-cell lymphoma.	CD79B
32510610	10.1002/hon.2761	2020	On point in primary CNS lymphoma.	CD79B
32606733	10.2147/OTT.S219449	2020	Profile of Polatuzumab Vedotin in the Treatment of Patients with Relapsed/Refractory Non-Hodgkin Lymphoma: A Brief Report on the Emerging Clinical Data.	CD79B
32641598	10.3960/jslrt.20010	2020	Clinicopathological significance of CD79a expression in classic Hodgkin lymphoma.	CD79B
32695560	10.2176/nmccrj.cr.2019-0241	2020	Primary Central Nervous System Methotrexate-associated Lymphoproliferative Disorder in a Patient with Rheumatoid Arthritis: Case Report and Review of Literature.	CD79B
32700586	10.1080/17474086.2020.1795828	2020	An evaluation of polatuzumab vedotin for the treatment of patients with diffuse large B-cell lymphoma.	CD79B
32700972	10.1080/13543784.2020.1800638	2020	Polatuzumab vedotin: an investigational anti-CD79b antibody drug conjugate for the treatment of diffuse large B-cell lymphoma.	CD79B
32736575	10.1186/s12885-020-07198-1	2020	Novel bioinformatic classification system for genetic signatures identification in diffuse large B-cell lymphoma.	CD79B
32745612	10.1016/j.jmoldx.2020.07.002	2020	Analysis of Driver Mutational Hot Spots in Blood-Derived Cell-Free DNA of Patients with Primary Central Nervous System Lymphoma Obtained before Intracerebral Biopsy.	CD79B
32770353	10.1007/s00280-020-04119-8	2020	Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.	CD79B
32864130	10.1186/s40364-020-00214-3	2020	A genetic predictive model for precision treatment of diffuse large B-cell lymphoma with early progression.	CD79B
32932517	10.1182/blood.2020005857	2020	The dangers of déjà vu: memory B cells as the cells of origin of ABC-DLBCLs.	CD79B
32985934	10.1080/17512433.2020.1826303	2020	Antibody-drug conjugates for previously treated aggressive lymphomas: focus on polatuzumab vedotin.	CD79B
33050534	10.3390/cancers12102913	2020	Oncogenic Mutations of MYD88 and CD79B in Diffuse Large B-Cell Lymphoma and Implications for Clinical Practice.	CD79B
33067267	10.1158/0008-5472.CAN-20-2425	2020	A Hyperactive RelA/p65-Hexokinase 2 Signaling Axis Drives Primary Central Nervous System Lymphoma.	CD79B
33173488	10.1159/000510403	2020	High-Grade Epstein-Barr Virus-Negative Biphenotypic Lymphoma with Expression of B- and T-Cell Markers and Leukemia Presentation: Case Report and Literature Review.	CD79B
33188997	10.1016/j.ctarc.2020.100235	2020	Activity of ibrutinib plus R-CHOP in diffuse large B-cell lymphoma: Response, pharmacodynamic, and biomarker analyses of a phase Ib study.	CD79B
33202794	10.3390/ijms21228553	2020	Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.	CD79B
33252851	10.1002/ctm2.221	2020	Influence of oncogenic mutations and tumor microenvironment alterations on extranodal invasion in diffuse large B-cell lymphoma.	CD79B
29734251	10.1097/PAI.0000000000000585	2019	MYD88, CARD11, and CD79B Oncogenic Mutations are Rare Events in the Indian Cohort of De Novo Nodal Diffuse Large B-Cell Lymphoma.	CD79B
29931583	10.1007/s10637-018-0623-8	2019	Dual targeting of bromodomain-containing 4 by AZD5153 and BCL2 by AZD4320 against B-cell lymphomas concomitantly overexpressing c-MYC and BCL2.	CD79B
30390359	10.1111/ejh.13191	2019	CD79B mutations in primary vitreoretinal lymphoma: Diagnostic and prognostic potential.	CD79B
30623224	10.1007/s00347-018-0840-8	2019	[New molecular pathological strategies for malignant iris tumors].	CD79B
30683910	10.1038/s41375-019-0380-5	2019	Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas.	CD79B
30696890	10.1038/s41598-018-37273-4	2019	Multi-omics dataset to decipher the complexity of drug resistance in diffuse large B-cell lymphoma.	CD79B
30723112	10.1182/bloodadvances.2018027672	2019	<i>MYD88</i> L265P mutation and <i>CDKN2A</i> loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas.	CD79B
30797915	10.1016/j.wneu.2019.01.298	2019	Intracranial Cell Lymphomas That Mimic Meningiomas: Case Report To Understand Complex Genetic, Radiologic, and Histopathologic Entities.	CD79B
30815927	10.1111/cas.13983	2019	Phase I study of tirabrutinib (ONO-4059/GS-4059) in patients with relapsed or refractory B-cell malignancies in Japan.	CD79B
30819916	10.3324/haematol.2018.212811	2019	A B-cell receptor-related gene signature predicts response to ibrutinib treatment in mantle cell lymphoma cell lines.	CD79B
30859597	10.1002/ajh.25460	2019	Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment.	CD79B
31077558	10.1002/cyto.b.21785	2019	Differential Expression of CD43, CD81, and CD200 in Classic Versus Variant Hairy Cell Leukemia.	CD79B
31101488	10.1016/S1470-2045(19)30182-2	2019	Targeted therapies make room, anti-CD79b agents are coming.	CD79B
31101489	10.1016/S1470-2045(19)30091-9	2019	Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study.	CD79B
31150604	10.1016/j.jid.2019.05.008	2019	Mutations of the B-Cell Receptor Pathway Confer Chemoresistance in Primary Cutaneous Diffuse Large B-Cell Lymphoma Leg Type.	CD79B
31242994	10.1158/2159-8290.CD-NB2019-076	2019	Polatuzumab Vedotin Approved for DLBCL.	CD79B
31270798	10.1111/bph.14784	2019	Evaluation and use of an anti-cynomolgus monkey CD79b surrogate antibody-drug conjugate to enable clinical development of polatuzumab vedotin.	CD79B
31292368	10.7888/juoeh.41.225	2019	[Two Resected Cases of Primary Pulmonary Mucosa-Associated Lymphoid Tissue Lymphoma, Differently Diagnosed in Chest Tomography Scan].	CD79B
31335415	10.1097/DAD.0000000000001347	2019	Cutaneous B-Cell Lymphoblastic Lymphoma.	CD79B
31352604	10.1007/s40265-019-01175-0	2019	Polatuzumab Vedotin: First Global Approval.	CD79B
31378966	10.1002/ajh.25600	2019	Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network.	CD79B
31403034	10.3389/fonc.2019.00683	2019	Comprehensive Genomic Profiling of EBV-Positive Diffuse Large B-cell Lymphoma and the Expression and Clinicopathological Correlations of Some Related Genes.	CD79B
31436356	10.1111/cas.14176	2019	Mutations found in cell-free DNAs of patients with malignant lymphoma at remission can derive from clonal hematopoiesis.	CD79B
31439577	10.1158/1078-0432.CCR-19-1337	2019	Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19.	CD79B
31522426	10.1007/978-1-4939-9650-6_17	2019	Clinical Flow-Cytometric Testing in Chronic Lymphocytic Leukemia.	CD79B
31565447	10.1155/2019/1586328	2019	Plasmablastic Lymphoma, a Rare Entity in Bone Marrow with Unusual Immunophenotype and Challenging Differential Diagnosis.	CD79B
31592789	10.1097/WCO.0000000000000759	2019	Molecular profiling of primary central nervous system lymphomas - predictive and prognostic value?	CD79B
31806993	10.2147/OTT.S227122	2019	Genomic Alterations In Primary Cardiac Diffuse Large B Cell Lymphoma: A Case Report And Literature Review.	CD79B
31872533	10.1111/pin.12871	2019	Anaplastic variant of diffuse large B-cell lymphoma: Reappraisal as a nodal disease with sinusoidal involvement.	CD79B
32063711	10.2147/OTT.S222189	2019	Prevalence And Clinical Significance Of Oncogenic <i>CD79B</i> And <i>MYD88</i> Mutations In Primary Testicular Diffuse Large B-Cell Lymphoma: A Retrospective Study In China.	CD79B
28109040	10.1002/cyto.b.21512	2018	Composite mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma.	CD79B
28187524	10.1002/cyto.b.21517	2018	Phenotypic Characterization of Trisomy 12 Monoclonal B-Cell Lymphocytosis.	CD79B
28713070	10.4274/tjh.2017.0085	2018	The Role of CD200 and CD43 Expression in Differential Diagnosis between Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma.	CD79B
28868954	10.1080/10428194.2017.1370546	2018	Mutational frequencies of CD79B and MYD88 vary greatly between primary testicular DLBCL and gastrointestinal DLBCL.	CD79B
29220870	10.1002/cyto.b.21607	2018	Quantitative assessment of informative immunophenotypic markers increases the diagnostic value of immunophenotyping in mature CD5-positive B-cell neoplasms.	CD79B
29289361	10.1016/j.blre.2017.12.001	2018	The pathobiology of primary testicular diffuse large B-cell lymphoma: Implications for novel therapies.	CD79B
29472356	10.3324/haematol.2017.184325	2018	A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial.	CD79B
29514783	10.1182/blood-2017-12-822817	2018	High prevalence of <i>MYD88</i> and <i>CD79B</i> mutations in intravascular large B-cell lymphoma.	CD79B
29568849	10.11622/smedj.2018030	2018	Intravascular large B-cell lymphoma presenting as panniculitis clinically: a case report.	CD79B
29641966	10.1056/NEJMoa1801445	2018	Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.	CD79B
29642007	10.1016/j.celrep.2018.03.069	2018	How Biophysical Forces Regulate Human B Cell Lymphomas.	CD79B
29669863	10.15252/embj.201797980	2018	Continuous signaling of CD79b and CD19 is required for the fitness of Burkitt lymphoma B cells.	CD79B
29807508	10.1177/0300985818777035	2018	Canine Splenic Nodular Lymphoid Lesions: Immunophenotyping, Proliferative Activity, and Clonality Assessment.	CD79B
29878045	10.1093/annonc/mdy133	2018	Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.	CD79B
29891112	10.1016/j.critrevonc.2018.05.010	2018	Molecular analysis in liquid biopsies for diagnostics of primary central nervous system lymphoma: Review of literature and future opportunities.	CD79B
29895903	10.1038/s41408-018-0089-0	2018	Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay.	CD79B
29925955	10.1038/s41586-018-0290-0	2018	A multiprotein supercomplex controlling oncogenic signalling in lymphoma.	CD79B
29931605	10.1007/s11864-018-0555-8	2018	Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence.	CD79B
29937999	10.18632/oncotarget.25463	2018	Target amplicon exome-sequencing identifies promising diagnosis and prognostic markers involved in RTK-RAS and PI3K-AKT signaling as central oncopathways in primary central nervous system lymphoma.	CD79B
29967210	10.1212/WNL.0000000000005735	2018	Teaching NeuroImages: Presentation of diffuse large B-cell lymphoma with bilateral sequential oculomotor neuropathy.	CD79B
30146835	10.7754/Clin.Lab.2018.180320	2018	Diffuse Large B Cell Lymphoma Coexistent with Follicular Cell Lymphoma.	CD79B
30171453	10.1007/s11060-018-2990-6	2018	Characterization of genomic alterations in primary central nervous system lymphomas.	CD79B
30190015	10.1016/j.hoc.2018.05.007	2018	Working Toward a Genomic Prognostic Classification of Waldenström Macroglobulinemia: C-X-C Chemokine Receptor Type 4 Mutation and Beyond.	CD79B
30227305	10.1016/j.neo.2018.08.012	2018	Analysis of Genomic Alteration in Primary Central Nervous System Lymphoma and the Expression of Some Related Genes.	CD79B
30243141	10.1016/j.legalmed.2018.09.001	2018	Sudden unexpected death with primary adrenal lymphoma.	CD79B
30294590	10.3389/fonc.2018.00382	2018	Detection of the <i>MYD88</i> p.L265P Mutation in the CSF of a Patient With Secondary Central Nervous System Lymphoma.	CD79B
27297871	10.1111/his.13015	2017	Recurrent mutations in genes involved in nuclear factor-κB signalling in nodal marginal zone lymphoma-diagnostic and therapeutic implications.	CD79B
27549353	10.1111/vco.12262	2017	Evaluation of Pax5 expression and comparison with BLA.36 and CD79αcy in feline non-Hodgkin lymphoma.	CD79B
27687087	10.1080/10428194.2016.1213836	2017	Nodal marginal zone lymphoma: mutation status analyses of CD79A, CD79B, and MYD88 reveal no specific recurrent lesions.	CD79B
27915469	10.1002/cncr.30404	2017	MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma.	CD79B
27923841	10.1158/1078-0432.CCR-16-1922	2017	Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P-Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases.	CD79B
28009435	10.1111/bph.13697	2017	Anti-CD22 and anti-CD79b antibody-drug conjugates preferentially target proliferating B cells.	CD79B
28011673	10.1182/blood-2016-05-718494	2017	Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling.	CD79B
28073005	10.1016/j.ccell.2016.12.003	2017	Simultaneous Inhibition of PI3Kδ and PI3Kα Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-κB and AKT.	CD79B
28153771	10.1016/j.ebiom.2017.01.027	2017	B-cell Function Gene Mutations in Diffuse Large B-cell Lymphoma: A Retrospective Cohort Study.	CD79B
28248816	10.1097/PAS.0000000000000828	2017	TdT-positive Infiltrate in Inflamed Pediatric Kidney: A Potential Diagnostic Pitfall.	CD79B
28319526	10.1097/PAS.0000000000000836	2017	Anaplastic Variant of Diffuse Large B-cell Lymphoma Displays Intricate Genetic Alterations and Distinct Biological Features.	CD79B
28341730	10.3324/haematol.2016.161893	2017	Combination of ibrutinib and chemotherapy produced a durable remission in multiply relapsed diffuse large B-cell lymphoma leg type with mutant <i>MYD88</i> and wildtype <i>CD79</i>.	CD79B
28368423	10.1038/onc.2017.95	2017	Myc enhances B-cell receptor signaling in precancerous B cells and confers resistance to Btk inhibition.	CD79B
28479318	10.1016/j.jid.2017.04.010	2017	Identification of Somatic Mutations in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type by Massive Parallel Sequencing.	CD79B
28552327	10.1016/j.ccell.2017.04.012	2017	Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma.	CD79B
28612664	10.1177/1066896917714325	2017	Primary Central Nervous System T-Cell Lymphoma With Aberrant Expression of CD20 and CD79a: A Diagnostic Pitfall.	CD79B
28619981	10.1158/2159-8290.CD-17-0613	2017	Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.	CD79B
28664939	10.1038/modpathol.2017.58	2017	Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms.	CD79B
28682481	10.1002/path.4933	2017	Significant association between TNFAIP3 inactivation and biased immunoglobulin heavy chain variable region 4-34 usage in mucosa-associated lymphoid tissue lymphoma.	CD79B
28701369	10.1084/jem.20161454	2017	Synergistic cooperation and crosstalk between <i>MYD88<sup>L265P</sup></i> and mutations that dysregulate CD79B and surface IgM.	CD79B
28791394	10.3892/mmr.2017.7158	2017	Identification of key genes and pathways associated with classical Hodgkin lymphoma by bioinformatics analysis.	CD79B
28803429	10.1007/s00277-017-3094-7	2017	Patients with primary breast and primary female genital tract diffuse large B cell lymphoma have a high frequency of MYD88 and CD79B mutations.	CD79B
28841204	10.1038/bcj.2017.72	2017	From Waldenström's macroglobulinemia to aggressive diffuse large B-cell lymphoma: a whole-exome analysis of abnormalities leading to transformation.	CD79B
28856744	10.1111/neup.12405	2017	Frequency of MYD88 and CD79B mutations, and MGMT methylation in primary central nervous system diffuse large B-cell lymphoma.	CD79B
28864640	10.1158/2159-8290.CD-17-0714	2017	Spotlight on Ibrutinib in PCNSL: Adding Another Feather to Its Cap.	CD79B
28884033	10.1155/2017/6891957	2017	High-Grade B-Cell Neoplasm with Surface Light Chain Restriction and Tdt Coexpression Evolved in a <i>MYC</i>-Rearranged Diffuse Large B-Cell Lymphoma: A Dilemma in Classification.	CD79B
28892912	10.7860/JCDR/2017/27149.10190	2017	Important Diagnostic Clues for Diagnosing Splenic Marginal Zone Lymphoma in Absence of Splenic Histology.	CD79B
28922238	10.1097/WCO.0000000000000492	2017	Primary central nervous system lymphoma: time for diagnostic biomarkers and biotherapies?	CD79B
28993276	10.1016/j.humpath.2017.09.013	2017	A distinctive subgroup of oral EBV+ B-cell neoplasm with polymorphous features is potentially identical to EBV+ mucocutaneous ulcer.	CD79B
29025291	10.1556/650.2017.30868	2017	[Waldenström's macroglobulinemia and its individualized therapy options].	CD79B
29035453	10.7754/Clin.Lab.2017.170406	2017	Immunophenotyping of Chronic Lymphocytic Leukemia.	CD79B
29062027	10.1038/s41467-017-01257-1	2017	Harnessing a catalytic lysine residue for the one-step preparation of homogeneous antibody-drug conjugates.	CD79B
29125235	10.1002/cam4.1257	2017	Comparison of the mRNA expression profile of B-cell receptor components in normal CD5-high B-lymphocytes and chronic lymphocytic leukemia: a key role of ZAP70.	CD79B
29245897	10.18632/oncotarget.18502	2017	Comparative analysis of primary <i>versus</i> relapse/refractory DLBCL identifies shifts in mutation spectrum.	CD79B
29262531	10.18632/oncotarget.21986	2017	Mutational profile of primary breast diffuse large B-cell lymphoma.	CD79B
25612555	10.1002/cyto.b.21227	2016	The utility of multiparametric seven-color flow cytometry in the detection of double hit lymphoma in ascitic fluid samples.	CD79B
26111727	10.1111/nan.12259	2016	Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas.	CD79B
26318093	10.1016/j.critrevonc.2015.08.014	2016	A review of monoclonal antibody therapies in lymphoma.	CD79B
26647218	10.1158/1078-0432.CCR-15-2123	2016	Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas.	CD79B
26699656	10.3109/10428194.2015.1113276	2016	CD79B limits response of diffuse large B cell lymphoma to ibrutinib.	CD79B
26752547	10.1097/PAS.0000000000000592	2016	Frequent MYD88 L265P and CD79B Mutations in Primary Breast Diffuse Large B-Cell Lymphoma.	CD79B
26773040	10.1182/blood-2015-09-672352	2016	Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease.	CD79B
26826778	10.1016/j.gastrohep.2015.12.001	2016	[Intestinal infiltration of high-grade large T-cell non-Hodgkin lymphoma with cyclin-D1 overexpression and aberrant CD79a expression in a patient with a diagnosis of tumour stage mycosis fungoides].	CD79B
26879426	10.3760/cma.j.issn.0529-5807.2016.02.002	2016	[Diffuse large B-cell lymphoma with aberrant expression of CD56: a clinicopathologic and immunohistochemical study].	CD79B
27010137		2016	Mutational status of EZH2 and CD79B hot spots in mature B-cell non-Hodgkin's lymphomas: novel CD79B variations have been revealed.	CD79B
27010357	10.1111/aos.13020	2016	Lacrimal gland extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue-type associated with massive amyloid deposition.	CD79B
27048211	10.1182/blood-2015-11-684183	2016	B-cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice.	CD79B
27198204	10.1038/leu.2016.135	2016	Distinct genetic evolution patterns of relapsing diffuse large B-cell lymphoma revealed by genome-wide copy number aberration and targeted sequencing analysis.	CD79B
27262792	10.1016/j.semcancer.2016.05.002	2016	Mechanisms of NF-κB deregulation in lymphoid malignancies.	CD79B
27521317	10.1016/j.clml.2016.02.032	2016	Immunophenotypic Characterization of Cytogenetic Subgroups in Egyptian Pediatric Patients With B-Cell Acute Lymphoblastic Leukemia.	CD79B
27526684	10.1111/ejh.12792	2016	Rewired NFκB signaling as a potentially actionable feature of activated B-cell-like diffuse large B-cell lymphoma.	CD79B
27559941	10.1097/MD.0000000000004128	2016	Development-associated immunophenotypes reveal the heterogeneous and individualized early responses of adult B-acute lymphoblastic leukemia.	CD79B
27590508	10.18632/oncotarget.11740	2016	Transcriptomic and functional pathways analysis of ascorbate-induced cytotoxicity and resistance of Burkitt lymphoma.	CD79B
27600807	10.1007/s00428-016-2012-z	2016	Cellular-level characterization of B cells infiltrating pulmonary MALT lymphoma tissues.	CD79B
25030036	10.3109/10428194.2014.944522	2015	Prevalence of targetable oncogenic mutations and genomic alterations in Epstein-Barr virus-associated diffuse large B-cell lymphoma of the elderly.	CD79B
25347427	10.3109/10428194.2014.979413	2015	Primary diffuse large B-cell lymphomas of central nervous system exhibit remarkably high prevalence of oncogenic MYD88 and CD79B mutations.	CD79B
25391967	10.1007/s11060-014-1655-3	2015	Differential expression of Toll-like receptor (TLR) and B cell receptor (BCR) signaling molecules in primary diffuse large B-cell lymphoma of the central nervous system.	CD79B
25414443	10.1182/blood-2014-07-587840	2015	Therapeutic targeting of the BCR-associated protein CD79b in a TCR-based approach is hampered by aberrant expression of CD79b.	CD79B
25417998	10.1002/ajh.23904	2015	CD20-negative diffuse large B-cell lymphoma presenting with lactic acidosis.	CD79B
25484043	10.4161/19420862.2014.979081	2015	Extensive crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in human lymphoma cells.	CD79B
25529125	10.1016/j.humpath.2014.10.021	2015	Lymphoblastic transformation of follicular lymphoma: a clinicopathologic and molecular analysis of 7 patients.	CD79B
25595795	10.1016/j.cgh.2015.01.003	2015	A Rare Case of Diffuse Polyps of Small Intestine With Abdominal Mass.	CD79B
25623213	10.1158/1078-0432.CCR-14-1561	2015	The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs.	CD79B
25639261	10.1002/eji.201545464	2015	Rehabilitation or the death penalty: autoimmune B cells in the dock.	CD79B
25643939	10.1111/bjh.13293	2015	Absence of CXCR4 mutations but high incidence of double mutant in CD79A/B and MYD88 in primary central nervous system lymphoma.	CD79B
25708834	10.1038/leu.2015.48	2015	Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes.	CD79B
25807917	10.1002/cncy.21535	2015	Multiplex sequencing for EZH2, CD79B, and MYD88 mutations using archival cytospin preparations from B-cell non-Hodgkin lymphoma aspirates previously tested for MYC rearrangement and IGH/BCL2 translocation.	CD79B
25840969	10.1158/1078-0432.CCR-14-2035	2015	A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs.	CD79B
25925618	10.1016/S1470-2045(15)70161-0	2015	Antibody-drug conjugates in non-Hodgkin lymphoma.	CD79B
25925619	10.1016/S1470-2045(15)70128-2	2015	Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.	CD79B
25933603	10.1186/s13104-015-1132-x	2015	Plasmablastic lymphoma of the oral cavity with breast recurrence: a case report.	CD79B
25991819	10.1158/1078-0432.CCR-14-2116	2015	Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas.	CD79B
26064133	10.1155/2015/953297	2015	Disseminated Gastric MALT Lymphoma with Monoclonal Gammopathy, t(11;18)(q21;q21), and Subsequent Development of T-Large Granular Lymphocytic Leukemia: A Case Report and Review of the Literature.	CD79B
26193343	10.1038/nm.3884	2015	Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.	CD79B
26194424	10.1007/s11912-015-0466-9	2015	Development and Integration of Antibody-Drug Conjugate in Non-Hodgkin Lymphoma.	CD79B
26307535	10.1182/blood-2015-06-649905	2015	Cell of origin of transformed follicular lymphoma.	CD79B
26483459	10.1073/pnas.1514944112	2015	Survival of human lymphoma cells requires B-cell receptor engagement by self-antigens.	CD79B
26515759	10.1186/s13045-015-0218-1	2015	Establishment and characterization of a novel MYC/BCL2 double-hit diffuse large B cell lymphoma cell line, RC.	CD79B
26517678	10.18632/oncotarget.5425	2015	Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.	CD79B
26540570	10.18632/oncotarget.6273	2015	Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma.	CD79B
26588248	10.1371/journal.pone.0143216	2015	Conditional Expression of E2A-HLF Induces B-Cell Precursor Death and Myeloproliferative-Like Disease in Knock-In Mice.	CD79B
26639163	10.1038/srep17868	2015	Coordinated loss of microRNA group causes defenseless signaling in malignant lymphoma.	CD79B
23737093	10.1007/s00277-013-1810-5	2014	A mimicking multiple liver metastasis of breast cancer by recurrent B lymphoblastic leukemia.	CD79B
24169729	10.1007/s00431-013-2181-6	2014	The emergence of CD20-/CD19- tumor cells after rituximab therapy for Epstein-Barr virus-associated post-transplant lymphoproliferative disorder complicated with hemophagocytic lymphohistiocytosis.	CD79B
24240734	10.1007/s00401-013-1202-x	2014	Systems biology of primary CNS lymphoma: from genetic aberrations to modeling in mice.	CD79B
24253023	10.1038/leu.2013.348	2014	High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma.	CD79B
24327543	10.1002/gcc.22126	2014	Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell lymphoma.	CD79B
24444466	10.1016/j.humpath.2013.10.023	2014	CD79B and MYD88 mutations in diffuse large B-cell lymphoma.	CD79B
24548411	10.1016/j.bbrc.2014.02.037	2014	IgG1 cytoplasmic tail is essential for cell surface expression in Igβ down-regulated cells.	CD79B
24576169	10.3109/10428194.2014.896006	2014	Auer rod-like inclusions in the cytoplasm of splenic lymphoma cells.	CD79B
24795275	10.1016/j.endonu.2014.03.005	2014	Hypothalamic evanescent lesion by diffuse large B-cell lymphoma.	CD79B
24841238	10.1371/journal.pone.0098315	2014	Anti-CD22/CD20 Bispecific antibody with enhanced trogocytosis for treatment of Lupus.	CD79B
24876818	10.5114/wo.2013.38570	2014	Possible role of CD22, CD79b and CD20 expression in distinguishing small lymphocytic lymphoma from chronic lymphocytic leukemia.	CD79B
24970810	10.18632/oncotarget.2080	2014	Mutational analysis of primary central nervous system lymphoma.	CD79B
25194535		2014	A case of t(14; 18)-negative follicular lymphoma with atypical immunophenotype: usefulness of immunoarchitecture of Ki67, CD79a and follicular dendritic cell meshwork in making the diagnosis.	CD79B
25275047		2014	Activating mutations affecting the NF-kappa B pathway and EZH2-mediated epigenetic regulation are rare events in primary mediastinal large B-cell lymphoma.	CD79B
25501023	10.1038/bcj.2014.87	2014	Diffuse large B cell lymphomas relapsing in the CNS lack oncogenic MYD88 and CD79B mutations.	CD79B
26011976		2014	Mantle cell lymphoma in a lacrimal gland in a female and a review of the literature.	CD79B
22296667	10.1111/j.1476-5829.2011.00317.x	2013	Clinical, histopathological and immunohistochemical characterization of canine indolent lymphoma.	CD79B
22776235	10.5732/cjc.012.10041	2013	Individualized leukemia cell-population profiles in common B-cell acute lymphoblastic leukemia patients.	CD79B
23174882	10.1038/leu.2012.280	2013	Role of early B-cell factor 1 (EBF1) in Hodgkin lymphoma.	CD79B
23361872	10.1002/cncy.21262	2013	EZH2 and CD79B mutational status over time in B-cell non-Hodgkin lymphomas detected by high-throughput sequencing using minimal samples.	CD79B
23372794	10.1371/journal.pone.0054938	2013	Cis and trans regulatory mechanisms control AP2-mediated B cell receptor endocytosis via select tyrosine-based motifs.	CD79B
23378931	10.1155/2013/252318	2013	CD79B and MYD88 Mutations in Splenic Marginal Zone Lymphoma.	CD79B
23396434	10.1684/abc.2012.0782	2013	[Mantle cell lymphoma diagnosis].	CD79B
23405135	10.1371/journal.pone.0055324	2013	Horizontal transmission of malignancy: in-vivo fusion of human lymphomas with hamster stroma produces tumors retaining human genes and lymphoid pathology.	CD79B
23444036	10.1177/0300985813478210	2013	Canine lymphomas: association of classification type, disease stage, tumor subtype, mitotic rate, and treatment with survival.	CD79B
23558558	10.1007/s00251-013-0698-5	2013	Cloning of a hamster anti-mouse CD79B antibody sequences and identification of a new hamster immunoglobulin lambda constant IGLC gene region.	CD79B
23562349	10.1179/1607845412Y.0000000037	2013	Primary bone marrow T-cell/histiocyte-rich large B-cell lymphoma: a diagnostic challenge.	CD79B
23821660	10.1182/blood-2012-12-473744	2013	Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab.	CD79B
24013661	10.1038/bcj.2013.28	2013	High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites.	CD79B
24060900	10.1016/j.semcancer.2013.09.001	2013	B-cell receptor signaling as a driver of lymphoma development and evolution.	CD79B
24447559		2013	[Primary cutaneous follicle centre lymphoma: report of a case].	CD79B
21900543	10.1177/0300985811419531	2012	Neurolymphomatosis in a dog with B-cell lymphoma.	CD79B
22064604	10.2310/JIM.0b013e31823908f9	2012	CD200 expression in B-cell chronic lymphoproliferative disorders.	CD79B
22102703	10.3324/haematol.2011.054080	2012	BCR and TLR signaling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas.	CD79B
22170090	10.1007/s12032-011-0136-1	2012	Outcome prediction of advanced mantle cell lymphoma by international prognostic index versus different mantle cell lymphoma indexes: one institution study.	CD79B
22308233	10.1177/0300985811432352	2012	Cutaneous lymphomas in European pet rabbits (Oryctolagus cuniculus).	CD79B
22431545	10.1309/AJCP3FEPX5BEEKGX	2012	Differentiating between Burkitt lymphoma and CD10+ diffuse large B-cell lymphoma: the role of commonly used flow cytometry cell markers and the application of a multiparameter scoring system.	CD79B
22567217	10.4081/hr.2012.e3	2012	Immunophenotyping of chronic B-cell neoplasms: flow cytometry versus immunohistochemistry.	CD79B
22800526	10.3760/cma.j.issn.0529-5807.2012.04.013	2012	[Intracranial plasmablastic lymphoma: report of a case].	CD79B
22800529	10.3760/cma.j.issn.0529-5807.2012.04.016	2012	[Neoplastic counterpart of interfollicular dendritic large B cells: report of a case].	CD79B
22808296		2012	Mutation analysis of NF-κB signal pathway-related genes in ocular MALT lymphoma.	CD79B
22844701	10.2478/v10181-011-0141-5	2012	High agreement of routine cytopathology and immunocytochemistry in canine lymphomas.	CD79B
22961721	10.1002/cyto.b.21038	2012	Flow cytometry CD45-negative B-NHL: a case report of a diffuse large B-cell lymphoma without extranodal involvement.	CD79B
23028900	10.1371/journal.pone.0045274	2012	Innate immunity and non-Hodgkin's lymphoma (NHL) related genes in a nested case-control study for gastric cancer risk.	CD79B
23032248		2012	Random skin biopsy of intravascular large B-cell lymphoma: a case report.	CD79B
23037779	10.1292/jvms.12-0100	2012	Overexpression of interleukin 2 receptor, thymidine kinase and immunoglobulin-associated alpha-1 messenger RNA in a clinical case of enzootic bovine leukosis.	CD79B
23072591	10.1186/1471-2407-12-478	2012	Phospho-specific flow cytometry identifies aberrant signaling in indolent B-cell lymphoma.	CD79B
23141946	10.1016/j.annpat.2012.07.021	2012	[Pitfalls and update in haematopathology. Case 7. Nodular lymphocyte predominant Hodgkin lymphoma].	CD79B
23236245	10.3748/wjg.v18.i45.6677	2012	Plasmablastic lymphoma of the small intestine: case report and literature review.	CD79B
23285191	10.1371/journal.pone.0052811	2012	VR09 cell line: an EBV-positive lymphoblastoid cell line with in vivo characteristics of diffuse large B cell lymphoma of activated B-cell type.	CD79B
23302315	10.3760/cma.j.issn.0529-5807.2012.10.013	2012	[Clear cell renal carcinoma coexisting with primary renal lymphoma: report of a case].	CD79B
23610978		2012	Difficulty in classifying a B cell chronic lymphoproliferative disorder CD5+.	CD79B
20337769	10.1111/j.1600-0560.2010.01538.x	2011	Cutaneous intravascular anaplastic large cell lymphoma.	CD79B
21145425	10.1016/j.cgh.2010.12.001	2011	Primary hepatic lymphoma: a large mass surrounding multiple intrahepatic vessels.	CD79B
21173233	10.1073/pnas.1008969108	2011	Critical role of PI3K signaling for NF-kappaB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells.	CD79B
21275949	10.1111/j.1365-2141.2010.08445.x	2011	Mutations of CD79A, CD79B and EZH2 genes in immunodeficiency-related non-Hodgkin lymphomas.	CD79B
21324920	10.1158/0008-5472.CAN-10-2525	2011	Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas.	CD79B
21337490	10.1002/cyto.b.20571	2011	Marginal zone B cell lymphomas with extensive plasmacytic differentiation are neoplasms of precursor plasma cells.	CD79B
21426801		2011	[Primary lymphoma of breast: a clinicopathologic and prognostic study of 40 cases].	CD79B
21487112	10.1182/blood-2010-12-324004	2011	New markers for minimal residual disease detection in acute lymphoblastic leukemia.	CD79B
21597060	10.3382/ps.2010-01295	2011	Allele-specific expression analysis reveals CD79B has a cis-acting regulatory element that responds to Marek's disease virus infection in chickens.	CD79B
21626771	10.2298/sarh1104229c	2011	[Progression of nodal marginal zone lymphoma into diffuse large B cell lymphoma in a patient with Sjögren's syndrome].	CD79B
21721452		2011	Utilization of a scoring system for diagnosis of chronic lymphocytic leukemia in Thai patients.	CD79B
21865343	10.1182/blood-2011-01-333682	2011	ZAP-70 enhances migration of malignant B lymphocytes toward CCL21 by inducing CCR7 expression via IgM-ERK1/2 activation.	CD79B
21914354		2011	[Diffuse large B-cell lymphoma of prostate: report of a case].	CD79B
21934229	10.4103/0377-4929.85103	2011	Primary lymphoma of the spermatic cord: a case report and review of the literature.	CD79B
21934679	10.1038/ni.2094	2011	Malignant pirates of the immune system.	CD79B
22124260	10.1097/PAT.0b013e32834c726f	2011	CD79a positive T cell lymphoma with bone marrow involvement.	CD79B
22177246		2011	[Clinicopathological features of Epstein-Barr virus-positive diffuse large B-cell lymphoma in elderly].	CD79B
20054396	10.1038/nature08638	2010	Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.	CD79B
20069343	10.1007/s11060-010-0112-1	2010	Immunohistological profiling by B-cell differentiation status of primary central nervous system lymphoma treated by high-dose methotrexate chemotherapy.	CD79B
20102401	10.1111/j.1365-2559.2009.03462.x	2010	BOB.1, CD79a and cyclin E are the most appropriate markers to discriminate classical Hodgkin's lymphoma from primary mediastinal large B-cell lymphoma.	CD79B
20350661	10.1053/j.seminhematol.2010.01.004	2010	Treatment of splenic marginal zone lymphoma: splenectomy versus rituximab.	CD79B
20391985	10.1159/000325015	2010	Can kidney posttransplant lymphoproliferative disorder be detected in voided urine? A case report.	CD79B
20453211	10.1177/104063871002200306	2010	Optimized processing of fine-needle lymph node biopsies for automated immunostaining.	CD79B
20480837		2010	Mucosa-associated lymphoid tissue lymphoma of the appendix vermiformis.	CD79B
20507729	10.5732/cjc.009.10573	2010	A liver-metastatic model of human primary gastric lymphoma in nude mice orthotopically constructed by using histologically intact patient specimens.	CD79B
20673534		2010	A principal case of multiple lymphoid collision tumors involving both B-cell chronic lymphocytic leukemia and metastatic malignant melanoma.	CD79B
20728042	10.1016/j.ejogrb.2010.05.015	2010	Bilateral primary breast lymphoma masquerading as lactating mastitis.	CD79B
20804679		2010	Cutaneous angiogenesis in patient with intravascular lymphoma (IVL): A case report.	CD79B
21055031		2010	[Morphologic diversity of plasma cell neoplasms].	CD79B
21092597		2010	[Diffuse large B-cell lymphoma following nodular lymphocyte predominant Hodgkin's lymphoma: report of a case].	CD79B
18838917	10.1097/PAI.0b013e3181845ef4	2009	Diagnostic utility of the B-cell lineage markers CD20, CD79a, PAX5, and CD19 in paraffin-embedded tissues from lymphoid neoplasms.	CD79B
19136769	10.4103/0377-4929.44952	2009	CD20 positivity in classical Hodgkin's lymphoma: Diagnostic challenge or targeting opportunity.	CD79B
19179973		2009	Meningeal relapse in a case of B acute lymphoblastic leukemia: the role of CD56 expression.	CD79B
19258515	10.1158/0008-5472.CAN-08-2250	2009	Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection.	CD79B
19573080	10.1111/j.1365-2141.2009.07790.x	2009	Common genetic variants in candidate genes and risk of familial lymphoid malignancies.	CD79B
19575872		2009	[Solitary plasmacytoma of spine: a clinical, radiologic and pathologic study of 13 cases].	CD79B
19633198	10.1182/blood-2009-02-205500	2009	Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma.	CD79B
19665353	10.1016/j.ijom.2009.07.010	2009	B-cell lymphoblastic lymphoma in the maxilla of a child: a rare case report.	CD79B
19773279	10.1136/oem.2008.044024	2009	Association between genetic variants in VEGF, ERCC3 and occupational benzene haematotoxicity.	CD79B
19808977	10.1158/1535-7163.MCT-09-0369	2009	In vivo effects of targeting CD79b with antibodies and antibody-drug conjugates.	CD79B
20067170		2009	Splenectomy--a therapeutic option in splenic marginal zone cell lymphoma.	CD79B
20079010		2009	[Lymphoplasmacytic lymphoma with Waldenström's macroglobulinemia: a clinicopathological and immunophenotypic study of 40 Chinese patients].	CD79B
20079012		2009	[Assessment of BIOMED-2 assays for detection of clonal Ig gene rearrangements in mature B-cell lymphomas].	CD79B
20079016		2009	[Clinicopathologic and immunohistochemical study of intra-abdominal non-Hodgkin B-cell lymphoma occurring in children].	CD79B
20079018		2009	[Clinicopathologic study of 15 splenectomy specimens of patients with hairy cell leukemia].	CD79B
17307369	10.1016/j.tvjl.2006.12.008	2008	Immunophenotyping of lymphosarcoma in South American camelids on six British premises.	CD79B
17628802	10.1007/s00277-007-0339-x	2008	Angiotropic large cell lymphoma presenting as intestinal obstruction.	CD79B
17629942	10.1016/j.leukres.2007.05.004	2008	The expression of cytoplasmic CD79a correlates with surface CD3 expression in childhood T-ALL lymphoblasts.	CD79B
18172310	10.1158/0008-5472.CAN-07-2778	2008	PAX5/TEL acts as a transcriptional repressor causing down-modulation of CD19, enhances migration to CXCL12, and confers survival advantage in pre-BI cells.	CD79B
18194817	10.1016/j.imlet.2007.11.023	2008	MHC class II structural requirements for the association with Igalpha/beta, and signaling of calcium mobilization and cell death.	CD79B
18288568	10.1007/s12185-008-0029-z	2008	B-Lymphoid and myeloid lineages biphenotypic acute leukemia with t(8;21)(q22;q22).	CD79B
18396780		2008	Cutaneous T-cell lymphoma in an African hedgehog (Atelerix albiventris).	CD79B
18566961	10.1002/path.2384	2008	The Epstein-Barr virus oncoprotein, latent membrane protein-1, reprograms germinal centre B cells towards a Hodgkin's Reed-Sternberg-like phenotype.	CD79B
18670352	10.1097/PAS.0b013e3181758806	2008	Fluorescence immunophenotypic and interphase cytogenetic characterization of nodal lymphoplasmacytic lymphoma.	CD79B
18686384		2008	[Burkitt's lymphoma of the spermatic cord: a case report and review of the literature].	CD79B
18712674	10.14670/HH-23.1223	2008	Immunophenotyping of acute lymphoblastic leukemia using immunohistochemistry in bone marrow biopsy specimens.	CD79B
18807227	10.1007/s12185-008-0153-9	2008	Primary hepatic marginal zone B cell lymphoma of mucosa-associated lymphoid tissue type: case report and review of the literature.	CD79B
18928873	10.1016/j.annpat.2007.11.009	2008	[Hodgkin's disease variant of Richter's syndrome. Two cases and literature review].	CD79B
19031716		2008	[Intravascular large B-cell lymphoma: report of two autopsy cases with literature review].	CD79B
17182546	10.4049/jimmunol.178.1.111	2007	Spleen tyrosine kinase (Syk), a novel target of curcumin, is required for B lymphoma growth.	CD79B
17300668	10.1111/j.1440-1827.2006.02058.x	2007	Development-dependent expression of cyclin D3 in precursor T-cell lymphoblastic leukemia/lymphoma.	CD79B
17317545	10.1016/j.carpath.2006.09.003	2007	Primary cardiac plasmablastic (diffuse large B-cell) lymphoma mimicking left ventricular aneurysm with mural thrombus.	CD79B
17317796	10.1354/vp.44-2-196	2007	High-throughput immunophenotyping of 43 ferret lymphomas using tissue microarray technology.	CD79B
17374736	10.1182/blood-2007-01-066704	2007	Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma.	CD79B
17395398	10.1016/j.prp.2007.01.009	2007	Russell body gastritis: expanding the spectrum of Helicobacter pylori - related diseases?	CD79B
17413989	10.1097/01.pgp.0000228144.59677.5a	2007	Lymphoma-like lesion of the uterine cervix: report of 12 cases of a rare entity.	CD79B
17414444	10.1097/01.dad.0000246178.70768.81	2007	Cutaneous involvement with Burkitt-like lymphoma.	CD79B
17548964	10.1620/tjem.212.199	2007	Malignant lymphoma arising from heterotopic Warthin's tumor in the neck: case report and review of the literature.	CD79B
17550863	10.3324/haematol.11081	2007	Aberrant positivity for CD79a in erythroid lineage cells--a finding observed in a subset of re-staging bone marrow trephine biopsies after treatment cell pain.	CD79B
17555446	10.1111/j.1365-2141.2007.06620.x	2007	Angioimmunoblastic T-cell lymphoma: histological progression associates with EBV and HHV6B viral load.	CD79B
17577503	10.1016/j.joms.2005.12.039	2007	Spontaneous regression of an HIV-associated plasmablastic lymphoma in the oral cavity: a case report.	CD79B
17706135		2007	[Distinction between lymphoma-like lesions and lymphoma of uterine cervix: a clinicopathologic study of 26 cases].	CD79B
17706154		2007	[Primary cardiac lymphoma of non-Hodgkin's lymphoma located in the right atrium: report of a case].	CD79B
17707828	10.1016/j.beha.2007.02.005	2007	The normal counterpart to the chronic lymphocytic leukemia B cell.	CD79B
17825145		2007	[Clinicopathologic features and treatment of primary splenic tumors].	CD79B
17883054		2007	Primary non-Hodgkin's lymphoma of breast: a case report.	CD79B
17917091	10.1007/s12032-007-0029-5	2007	Immunophenotypic profile and clinical characteristics in patients with advanced stage mantle cell lymphoma.	CD79B
17969988		2007	[Case of both T- and B-cell markers positive pyothorax-associated lymphoma].	CD79B
18019744		2007	Primary hepatic low-grade B-cell lymphoma of MALT-type associated with Helicobacter pylori infection.	CD79B
18039900	10.1354/vp.44-6-875	2007	Immunohistochemical detection of multiple myeloma 1/interferon regulatory factor 4 (MUM1/IRF-4) in canine plasmacytoma: comparison with CD79a and CD20.	CD79B
18307875		2007	[Mantle cell lymphoma: clinicopathologic features and prognostic factors of 102 cases occurring in Chinese patients].	CD79B
16304050	10.1182/blood-2005-09-3765	2006	Epigenetic processes play a major role in B-cell-specific gene silencing in classical Hodgkin lymphoma.	CD79B
16395706	10.1002/ijc.21762	2006	Cancer-associated carbohydrate identification in Hodgkin's lymphoma by carbohydrate array profiling.	CD79B
16468652		2006	[Solitary plasmacytoma: a clinicopathologic and immunophenotypic analysis of 43 cases].	CD79B
16531332	10.1080/08820130500496878	2006	A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry.	CD79B
16800918		2006	[Biological characteristics of hyperleukocytic acute leukemia].	CD79B
16877363	10.2353/ajpath.2006.060020	2006	Aberrant expression of ID2, a suppressor of B-cell-specific gene expression, in Hodgkin's lymphoma.	CD79B
16930333	10.1111/j.1440-1827.2006.02001.x	2006	Epstein-Barr virus-associated enteritis with multiple ulcers after stem cell transplantation: first histologically confirmed case.	CD79B
16938530	10.1016/j.humpath.2006.04.009	2006	Extra-oral plasmablastic lymphoma: report of a case and review of literature.	CD79B
16984613	10.1111/j.1440-1827.2006.02011.x	2006	Follicular lymphoma frequently originates in the salivary gland.	CD79B
16984625	10.1111/j.1440-1827.2006.02023.x	2006	Recurrent primary cutaneous large B-cell lymphoma after a long-term remission.	CD79B
17062357		2006	[Primary diffuse large B-cell lymphoma of the heart: a clinicopathological study].	CD79B
17069714		2006	[Diffuse large B-cell lymphoma of adrenal: report of a case].	CD79B
17134580		2006	[Post-transplant lymphoproliferative disorders: a report of two cases].	CD79B
17147246		2006	[Application of a four antibody (cMPO/cCD79aalpha/cCD3/CD45) combination to the diagnosis of acute leukemia expressing cross-lineage antigens].	CD79B
15693895	10.1111/j.1365-2559.2005.02046.x	2005	Composite marginal zone B-cell lymphoma and classical Hodgkin's lymphoma: a clinicopathological study of 12 cases.	CD79B
15743747	10.1309/FDGW-B5C2-MYRY-XH2E	2005	Chronic lymphocytic leukemia/small lymphocytic lymphoma associated with IgM paraprotein.	CD79B
15949264		2005	[A clinicopathological study of 96 cases of lymphoblastic lymphoma].	CD79B
15967459	10.1016/j.jmb.2005.05.032	2005	Patterned CpG methylation of silenced B cell gene promoters in classical Hodgkin lymphoma-derived and primary effusion lymphoma cell lines.	CD79B
16042680	10.1111/j.1365-2141.2005.05506.x	2005	Lymphoma and malignant vasovagal syndrome.	CD79B
16045788	10.1111/j.1365-2559.2005.02079.x	2005	Nodal peripheral T-cell lymphoma associated with Warthin's tumour.	CD79B
16091170		2005	[Clinicopathologic study of 369 B-cell non-Hodgkin lymphoma cases, with reference to the 2001 World Health Organization classification of lymphoid neoplasms].	CD79B
16105762	10.1532/IJH97.E0501	2005	Meningeal lymphomatosis as the first manifestation of splenic marginal zone lymphoma.	CD79B
16115242	10.1111/j.1365-2559.2005.02120.x	2005	Post-transplant lymphoproliferative disorder with Hodgkin's lymphoma and large B-cell lymphoma differentiation.	CD79B
16185500		2005	[Expression of Oct2 and its significance in lymphoma diagnosis].	CD79B
16185515		2005	[T cell/histiocyte-rich large B cell lymphoma].	CD79B
16191510	10.1309/3G1X-DX0D-VHBN-VKB4	2005	Immunophenotypic profile of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia.	CD79B
16213517	10.1016/j.jcpa.2005.05.004	2005	Immunohistochemical diagnosis of alimentary lymphomas and severe intestinal inflammation in cats.	CD79B
16270275	10.1111/j.1939-165x.2005.tb00076.x	2005	Multilobulated flower cells in a subcutaneous mass aspirate from a cat.	CD79B
16271957	10.1016/j.cancergencyto.2005.06.002	2005	CD79a expression in acute myeloid leukemia t(8;21) and the importance of cytogenetics in the diagnosis of leukemias with immunophenotypic ambiguity.	CD79B
16403258		2005	Comparative study of expressions of cytoplasmic CD79a and other B-lymphoid immunomarkers in acute leukemic cells.	CD79B
16545182		2005	[T-cell/histiocyte-rich B-cell lymphoma: histology, immunophenotype and differential diagnosis].	CD79B
14989776		2004	[Characteristic analysis of acute leukemia immunophenotyping in 180 cases by flow cytometry].	CD79B
15003483	10.1016/j.jcpa.2003.09.008	2004	The possible prognostic significance of immunophenotype in feline alimentary lymphoma: a pilot study.	CD79B
15166665	10.1097/01.pas.0000126781.87158.e3	2004	Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities.	CD79B
15168595	10.1532/ijh97.03156	2004	Epstein-Barr virus-associated composite lymphoma composed of peripheral T-cell lymphoma and an anaplastic variant of a diffuse large B-cell type of non-Hodgkin's lymphoma and strongly expressing p53 protein.	CD79B
15229149	10.1373/clinchem.2003.030114	2004	Differentiation of acute myeloid leukemia from B- and T-lineage acute lymphoid leukemias by real-time quantitative reverse transcription-PCR of lineage marker mRNAs.	CD79B
15254666		2004	Contribution of flow cytometric immunophenotyping and bone marrow trephine biopsy in the detection of lymphoid bone marrow infiltration in non-Hodgkin's lymphomas.	CD79B
15257313	10.1038/modpathol.3800227	2004	Analysis of transcription factor OCT.1, OCT.2 and BOB.1 expression using tissue arrays in classical Hodgkin's lymphoma.	CD79B
15265880	10.4049/jimmunol.173.3.1526	2004	Antigen-processing machinery in human dendritic cells: up-regulation by maturation and down-regulation by tumor cells.	CD79B
15338374	10.1007/s00535-004-1374-1	2004	Primary, solitary, adult T-cell leukemia / lymphoma of the descending colon.	CD79B
15370213	10.1080/10428190410001683769	2004	Usefulness of bone marrow aspiration for definite diagnosis of Asian variant of intravascular lymphoma: four autopsied cases.	CD79B
15483677	10.1038/sj.leu.2403531	2004	IgH DJ rearrangements within T-ALL correlate with cCD79a expression, an immature/TCRgammadelta phenotype and absence of IL7Ralpha/CD127 expression.	CD79B
15492262	10.1158/0008-5472.CAN-04-1865	2004	PAX5 expression in acute leukemias: higher B-lineage specificity than CD79a and selective association with t(8;21)-acute myelogenous leukemia.	CD79B
15544702	10.1186/1471-2407-4-80	2004	Neuroblastoma and pre-B lymphoma cells share expression of key transcription factors but display tissue restricted target gene expression.	CD79B
15551734	10.1097/00129039-200409000-00006	2004	Cutaneous immunocytoma: a clinical, histologic, and phenotypic study of 11 cases.	CD79B
15634450		2004	[Application of flow cytometry in the differential diagnosis of lymphoma/leukemia with aberrant antigen expression].	CD79B
15650271	10.1196/annals.1322.054	2004	Flow cytometric immunophenotyping analysis of patterns of antigen expression in non-Hodgkin's B cell lymphoma in samples obtained from different anatomic sites.	CD79B
15738870	10.1016/s0242-6498(04)94000-x	2004	[A-leukemic caecal myeloid sarcoma: a difficult diagnosis].	CD79B
15884290	10.4314/eamj.v81i4.9159	2004	Recurrent chylothorax in a patient with non-Hodgkins lymphoma: case report.	CD79B
12580968	10.1046/j.1365-2141.2003.04071.x	2003	Cell surface CD43 determination improves diagnostic precision in late B-cell diseases.	CD79B
12651942	10.1073/pnas.0735266100	2003	Somatic hypermutation of the B cell receptor genes B29 (Igbeta, CD79b) and mb1 (Igalpha, CD79a).	CD79B
12653584	10.5858/2003-127-0356-BALWCO	2003	Biphenotypic acute leukemia with coexpression of CD79a and markers of myeloid lineage.	CD79B
12720136	10.1053/sonc.2003.50046	2003	Differential diagnosis of Waldenstrom's macroglobulinemia from other low-grade B-cell lymphoproliferative disorders.	CD79B
12786898	10.1046/j.1365-2559.2003.01636.x	2003	Plasmablastic lymphoma in HIV+ patients: an expanding spectrum.	CD79B
12859745	10.1034/j.1600-0560.2003.00078.x	2003	Cutaneous B-cell lymphoma with loss of CD20 immunoreactivity after rituximab therapy.	CD79B
12962571		2003	Immunophenotypic characterization of normal peripheral blood B lymphocyte by flow cytometry: reference for diagnosis of chronic B cell leukemia/lymphoma.	CD79B
14579239	10.1002/hon.713	2003	Primary non-Hodgkin lymphoma of the humerus following traumatic injury: case report.	CD79B
14582135	10.1002/cyto.b.10049	2003	Pan B-cell markers are not redundant in analysis of chronic lymphocytic leukemia (CLL).	CD79B
14608905	10.1309/YCH8-DWUF-FQBK-GPVB	2003	The B-cell transcription factors BSAP, Oct-2, and BOB.1 and the pan-B-cell markers CD20, CD22, and CD79a are useful in the differential diagnosis of classic Hodgkin lymphoma.	CD79B
14614054	10.1097/01.MP.0000093627.51090.3F	2003	Expression of B-cell markers in classical hodgkin lymphoma: a tissue microarray analysis of 330 cases.	CD79B
14644508	10.1016/j.gene.2003.08.021	2003	Disruption of the PU.1 gene in chicken B lymphoma DT40 cells and its effect on reported target gene expression.	CD79B
11940479		2002	Translocation t(2;7)(p12;q21-22) with dysregulation of the CDK6 gene mapping to 7q21-22 in a non-Hodgkin's lymphoma with leukemia.	CD79B
11950916	10.1038/modpathol.3880541	2002	Peripheral T-cell lymphoma mimicking marginal zone B-cell lymphoma.	CD79B
11970976	10.4049/jimmunol.168.9.4344	2002	Transmodulation of BCR signaling by transduction-incompetent antigen receptors: implications for impaired signaling in anergic B cells.	CD79B
12115880	10.1002/path.1126	2002	Immunohistochemical detection of CD79a expression in precursor T cell lymphoblastic lymphoma/leukaemias.	CD79B
12354547	10.1053/jcpa.2002.0555	2002	Immunohistochemical characterization of lymphosarcoma in two alpacas (Lama pacos).	CD79B
12368180		2002	Relevance of CD79a expression for T-cell lineage attribution in CD7+/CD3- acute lymphoblastic leukemia.	CD79B
12384401	10.1182/blood.V100.9.3068	2002	The alternative transcript of CD79b is overexpressed in B-CLL and inhibits signaling for apoptosis.	CD79B
12429788	10.1097/01.MP.0000031710.32235.24	2002	Leukemic phase of B-cell lymphomas mimicking chronic lymphocytic leukemia and variants at presentation.	CD79B
12429796	10.1097/01.MP.0000032534.81894.B3	2002	MAL expression in lymphoid cells: further evidence for MAL as a distinct molecular marker of primary mediastinal large B-cell lymphomas.	CD79B
11235901	10.1038/modpathol.3880265	2001	Peripheral T-cell lymphoma with aberrant expression of CD79a and CD20: a diagnostic pitfall.	CD79B
11241503	10.1002/1097-0320(20010215)46:1&lt;23::aid-cyto1033&gt;3.0.co;2-z	2001	Optimal number of reagents required to evaluate hematolymphoid neoplasias: results of an international consensus meeting.	CD79B
11298107	10.1046/j.1365-2230.2001.00786.x	2001	Systemic B-cell lymphoma presenting as an isolated lesion on the ear.	CD79B
11368285	10.2165/00003495-200161050-00005	2001	Achieving optimal outcomes in chronic lymphocytic leukaemia.	CD79B
11372738	10.1007/BF02981944	2001	A Hodgkin's disease cell line, KM-H2, shows biphenotypic features of dendritic cells and B cells.	CD79B
11384666	10.1016/s0022-1759(01)00338-6	2001	Reference values for peripheral blood B-lymphocyte subpopulations: a basis for multiparametric immunophenotyping of abnormal lymphocytes.	CD79B
11396639	10.1097/00129039-200106000-00001	2001	CD79: a review.	CD79B
11419987	10.5858/2001-125-0958-CTCLLW	2001	CD79a(+) T-cell lymphoblastic lymphoma with coexisting Langerhans cell histiocytosis.	CD79B
11504918	10.1073/pnas.181206898	2001	CmC(A/T)GG DNA methylation in mature B cell lymphoma gene silencing.	CD79B
11553311	10.1034/j.1600-0560.2001.028009453.x	2001	Expression of cutaneous lymphocyte-associated antigen and TIA-1 by lymphocytes in pityriasis lichenoides et varioliformis acuta and lymphomatoid papulosis: immunohistochemical study.	CD79B
11564080	10.1046/j.1365-2141.2001.03019.x	2001	Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti-CD20): a retrospective cohort analysis.	CD79B
11697493	10.3109/10428190109099325	2001	Morphologically typical and atypical B-cell chronic lymphocytic leukemias display a different pattern of surface antigenic density.	CD79B
11697517	10.3109/10428190109099349	2001	Primary extramedullary plasmacytoma of the lacrimal gland.	CD79B
11706077	10.1038/modpathol.3880450	2001	Angiotropic lymphoma: an immunophenotypically and clinically heterogeneous lymphoma.	CD79B
11737305	10.1046/j.1365-2559.2001.01271.x	2001	Histological and immunohistochemical characterization of extranodal diffuse large-cell lymphomas with prominent spindle cell features.	CD79B
11778688	10.1023/a:1012904307579	2001	Molecular cytogenetic analysis of a novel high-grade canine T-lymphoblastic lymphoma demonstrating co-expression of CD3 and CD79a cell markers.	CD79B
11892366		2001	[Cytoimmunofluorometry in the diagnosis of MALT lymphoma of the gastrointestinal tract].	CD79B
10674895	10.3109/10428190009148844	2000	Chronic lymphoproliferative disorders: an integrated point of view for the differential diagnosis.	CD79B
10757332	10.1038/modpathol.3880041	2000	Sinusoidal CD30-positive large B-cell lymphoma: a morphologic mimic of anaplastic large cell lymphoma.	CD79B
10818680	10.1016/s0065-230x(00)79005-1	2000	The indispensable role of microenvironment in the natural history of low-grade B-cell neoplasms.	CD79B
10821487	10.1053/hp.2000.6551	2000	Clonality assessment of lymphoproliferative disorders by multiparameter flow cytometry of paraffin-embedded tissue: an additional diagnostic tool in surgical pathology.	CD79B
10874881	10.1309/G689-2J36-KCTC-WD5N	2000	Usefulness of CD79b expression in the diagnosis of B-cell chronic lymphoproliferative disorders.	CD79B
10874883	10.1309/391R-93YF-DB4D-1L35	2000	Flow cytometric detection of CD79a expression in T-cell acute lymphoblastic leukemias.	CD79B
10886208	10.1046/j.1365-2141.2000.02045.x	2000	Anaplastic large-cell lymphomas of B-cell phenotype are anaplastic lymphoma kinase (ALK) negative and belong to the spectrum of diffuse large B-cell lymphomas.	CD79B
10903747	10.4049/jimmunol.165.3.1427	2000	Aberrant trafficking of the B cell receptor Ig-alpha beta subunit in a B lymphoma cell line.	CD79B
10912936	10.1038/modpathol.3880133	2000	Immunoreactivity of B-cell markers (CD79a, L26) in rare cases of extranodal cytotoxic peripheral T- (NK/T-) cell lymphomas.	CD79B
11055871	10.1354/vp.37-5-465	2000	Progression of an orbital T-cell rich B-cell lymphoma to a B-cell lymphoma in a dog.	CD79B
11070128	10.1053/hupa.2000.18504	2000	Two cases of histiocytic necrotizing lymphadenitis (Kikuchi-Fujimoto's disease) following diffuse large B-cell lymphoma.	CD79B
11122144		2000	An Asian variant of intravascular large B-cell lymphoma: clinical, pathological and cytogenetic approaches to diffuse large B-cell lymphoma associated with haemophagocytic syndrome.	CD79B
11123762	10.1046/j.1440-1827.2000.01151.x	2000	Primary cutaneous B-cell lymphoma in Japanese patients.	CD79B
11131924	10.1007/s002770000200	2000	T-cell/natural killer cell lymphoblastic lymphoma with an unusual coexpression of B-cell antigens.	CD79B
11558462	10.1638/1042-7260(2000)031[0388:TCRBCL]2.0.CO;2	2000	T-cell-rich B-cell lymphoma in a ring-tailed lemur (Lemur catta).	CD79B
10048429	10.3109/10428199909058414	1999	Widespread B29 (CD79b) gene defects and loss of expression in chronic lymphocytic leukemia.	CD79B
10198699		1999	[Role of Epstein-Barr virus in the pathogenesis of lymphogranulomatosis. Immunohistochemical and molecular-biological (hybridization in situ) research].	CD79B
10213673	10.1053/jcpa.1998.0244	1999	B-cell (CD79a+) lymphoma affecting the tarsal joint synovia in a sheep.	CD79B
10319379		1999	B-chronic lymphocytic leukemia, small lymphocytic lymphoma, and lymphoplasmacytic lymphoma, including Waldenström's macroglobulinemia: a clinical, morphologic, and biologic spectrum of similar disorders.	CD79B
10329919		1999	Quantitative analysis of CD79b, CD5 and CD19 in mature B-cell lymphoproliferative disorders.	CD79B
10353002		1999	Expression of CD79a antigen in acute lymphoblastic leukaemias in children.	CD79B
10397328		1999	CD79a detected by ZL7.4 separates chronic lymphocytic leukemia from mantle cell lymphoma in the leukemic phase.	CD79B
10419594	10.1002/(SICI)1096-9896(199907)188:3&lt;267::AID-PATH357&gt;3.0.CO;2-N	1999	Gene rearrangements in T-cell lymphoblastic lymphoma.	CD79B
10587707	10.1093/ajcp/112.6.836	1999	Precursor B lymphoblastic lymphoma presenting as lytic bone lesions.	CD79B
11869528		1999	[A clinico-pathological and immunohistochemical study on anaplastic large cell lymphoma].	CD79B
9531288		1998	Asymmetrical phosphorylation and function of immunoreceptor tyrosine-based activation motif tyrosines in B cell antigen receptor signal transduction.	CD79B
9924428	10.1002/(SICI)1096-9896(1998100)186:2&lt;140::AID-PATH149&gt;3.0.CO;2-Y	1998	Co-expression of CD79a (JCB117) and CD3 by lymphoblastic lymphoma.	CD79B
8656670		1996	Differential expression of B29 (CD79b) and mb-1 (CD79a) proteins in acute lymphoblastic leukaemia.	CD79B
7539038	10.1084/jem.181.6.2077	1995	Identification of the tyrosine phosphatase PTP1C as a B cell antigen receptor-associated protein involved in the regulation of B cell signaling.	CD79B
